Windtree Therapeutics, a Nasdaq-listed biotech company, announced plans to purchase up to $700 million in BNB, the fifth-largest cryptocurrency, following its recent all-time high price. The company aims to enhance its balance sheet by investing in digital assets, raising up to $520 million specifically for BNB acquisitions. Windtree will utilize a $500 million equity line of credit and a $20 million stock-purchase agreement to finance these purchases. It has partnered with crypto exchange Kraken for custody and trading services as part of its BNB Crypto Treasury Strategy. Currently, BNB is trading around $769 and has a market cap of $106.9 billion. Following recent trends, a number of publicly traded companies are now diversifying their treasury holdings with cryptocurrencies, signaling a shift in traditional investment strategies. Windtree's stock has seen significant growth over the past month, increasing by 162%.

Source šŸ”—